Clinical experience of roxadustat in the treatment of chronic kidney disease with thalassemia
10.3760/cma.j.cn441217-20240122-00129
- VernacularTitle:罗沙司他治疗慢性肾脏病伴地中海贫血的临床经验
- Author:
Guangyu AO
1
;
Jing LI
1
;
Yuanyuan TANG
1
;
Min CHEN
1
Author Information
1. 成都市第一人民医院肾脏内科，成都 610095
- Publication Type:Journal Article
- Keywords:
Renal insufficiency, chronic;
Thalassemia;
Iron metabolism disorder;
Renal anemia;
Roxadustat
- From:
Chinese Journal of Nephrology
2024;40(12):968-971
- CountryChina
- Language:Chinese
-
Abstract:
Chronic kidney disease (CKD) patients with concurrent renal anemia and thalassemia present complex pathogenesis involving various iron metabolism disorders, which are among the key factors contributing to suboptimal therapeutic outcomes. This paper reports the clinical experience of treating five CKD stage 3-4 patients with thalassemia using roxadustat. The treatment outcomes demonstrated that all patients experienced significant improvements in anemia, and no cases of iron overload were observed throughout the follow-up period. These findings suggest that roxadustat effectively increases hemoglobin levels in patients with renal anemia and thalassemia while maintaining a low risk of iron overload, providing a potential therapeutic option for these challenging cases.
